Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya
Copyright © 2023 Elsevier B.V. All rights reserved..
BACKGROUND & AIMS: Directly observed therapy (DOT) maximizes adherence and minimizes treatment gaps. Peer case managers (PCM) have also shown promise as a component of integrated HCV treatment strategies. DOT and PCM-support have been underexplored, particularly in low- and middle-income countries (LMICs). The objective of this study was to evaluate predictors of sustained virologic response (SVR) among people who inject drugs (PWID) attending medication-assisted treatment (MAT) and needle and syringe programs (NSP) sites in Kenya.
METHODS: We recruited PWID accessing MAT and NSP in Nairobi and Coastal Kenya. PWID were treated with ledipasvir/sofosbuvir using DOT supported by PCMs. We used bivariate and multivariate logistic regression to examine the impact of sociodemographic, behavioral, and clinical factors on SVR.
RESULTS: Among 92 PWID who initiated HCV treatment, 79 (86%) were male with mean age of 36.3 years (SD=±6.5); 38 (41%) were HIV-positive, and 87 (95%) reported injecting drugs in the last 30 days. Just over half of participants were genotype 1a (55%), followed by genotype 4a (41%) and mixed 1a/4a (3%). Most participants, 85 (92%) completed treatment and 79 (86%) achieved SVR. While sociodemographic and behavioral factors including recent injection drug use were not significantly associated with achieving SVR, being fully adherent (p=0.042), number of doses taken (p=0.008) and treatment completion (p= 0.001) were associated with higher odds of achieving SVR.
CONCLUSIONS: DOT with PCM-support was an effective model for HCV treatment among PWID in this LMIC setting. Adherence was the most important driver of SVR suggesting DOT and PCM support can overcome other factors that might limit adherence. Further research is necessary to ascertain the effectiveness of other models of HCV care for PWID in LMICs given NSP and MAT access is variable, and DOT may not be sustainable with limited resources.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
The International journal on drug policy - 113(2023) vom: 01. März, Seite 103959 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Akiyama, Matthew J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.03.2023 Date Revised 02.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drugpo.2023.103959 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352681217 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352681217 | ||
| 003 | DE-627 | ||
| 005 | 20240302232121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drugpo.2023.103959 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM352681217 | ||
| 035 | |a (NLM)36758335 | ||
| 035 | |a (PII)S0955-3959(23)00008-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Akiyama, Matthew J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2023 | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: Directly observed therapy (DOT) maximizes adherence and minimizes treatment gaps. Peer case managers (PCM) have also shown promise as a component of integrated HCV treatment strategies. DOT and PCM-support have been underexplored, particularly in low- and middle-income countries (LMICs). The objective of this study was to evaluate predictors of sustained virologic response (SVR) among people who inject drugs (PWID) attending medication-assisted treatment (MAT) and needle and syringe programs (NSP) sites in Kenya | ||
| 520 | |a METHODS: We recruited PWID accessing MAT and NSP in Nairobi and Coastal Kenya. PWID were treated with ledipasvir/sofosbuvir using DOT supported by PCMs. We used bivariate and multivariate logistic regression to examine the impact of sociodemographic, behavioral, and clinical factors on SVR | ||
| 520 | |a RESULTS: Among 92 PWID who initiated HCV treatment, 79 (86%) were male with mean age of 36.3 years (SD=±6.5); 38 (41%) were HIV-positive, and 87 (95%) reported injecting drugs in the last 30 days. Just over half of participants were genotype 1a (55%), followed by genotype 4a (41%) and mixed 1a/4a (3%). Most participants, 85 (92%) completed treatment and 79 (86%) achieved SVR. While sociodemographic and behavioral factors including recent injection drug use were not significantly associated with achieving SVR, being fully adherent (p=0.042), number of doses taken (p=0.008) and treatment completion (p= 0.001) were associated with higher odds of achieving SVR | ||
| 520 | |a CONCLUSIONS: DOT with PCM-support was an effective model for HCV treatment among PWID in this LMIC setting. Adherence was the most important driver of SVR suggesting DOT and PCM support can overcome other factors that might limit adherence. Further research is necessary to ascertain the effectiveness of other models of HCV care for PWID in LMICs given NSP and MAT access is variable, and DOT may not be sustainable with limited resources | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Africa | |
| 650 | 4 | |a Direct-acting antivirals | |
| 650 | 4 | |a Hepatitis c virus | |
| 650 | 4 | |a Low- and middle-income countries | |
| 650 | 4 | |a Peer | |
| 650 | 4 | |a People who inject drugs | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Riback, Lindsey R |e verfasserin |4 aut | |
| 700 | 1 | |a Nyakowa, Mercy |e verfasserin |4 aut | |
| 700 | 1 | |a Musyoki, Helgar |e verfasserin |4 aut | |
| 700 | 1 | |a Lizcano, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, Abbe |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chenshu |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Josephine G |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Jack |e verfasserin |4 aut | |
| 700 | 1 | |a Vickerman, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Cherutich, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Kurth, Ann E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The International journal on drug policy |d 1996 |g 113(2023) vom: 01. März, Seite 103959 |w (DE-627)NLM089798821 |x 1873-4758 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:2023 |g day:01 |g month:03 |g pages:103959 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drugpo.2023.103959 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 2023 |b 01 |c 03 |h 103959 | ||